Gastrointestinal Symptom Events and Motility Alterations Associated With GLP ‐1 Receptor Agonists
Neurogastroenterology & Motility · 2026-10 · 38 (10)
DOI: 10.1111/nmo.70458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 18.10.2026. Verfasst von Julio Zuniga Cisneros und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Gastrointestinal Diseases, Gastrointestinal Motility, Hypoglycemic Agents. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Gastrointestinal symptom events (GISE) are common with glucagon‐like peptide‐1 receptor agonists (GLP‐1RA). We aimed to determine the prevalence of GISE and clinical factors associated with GISE.
Methods
An integrated platform database was used to collect real‐world data. Using a retrospective cohort study design, Kaplan–Meier analysis was used to estimate GISE‐free survival over 60 months. To identify predictors of GISE, the cohort was randomly split 80/20 into training and testing sets. A LASSO‐penalized Cox model was used to identify relevant associations, after which main‐effect and interaction models were constructed. Gastric emptying scintigraphy (GES) of solids was extracted from electronic medical records, where available.
Results
Among 78,277 patients, 87% reported no baseline GI symptoms. At 60 months, 53% reported at least one GISE, most commonly abdominal pain (28%) and nausea (25%). Women were at higher risk of GISE than men (Kaplan–Meier HR 1.4). In the prediction model, baseline diarrhea, constipation, abdominal pain, and nausea were associated with higher GISE risk (HRs 2.2, 2.0, 1.7, and 1.6, respectively), and male sex with lower risk (HR 0.79). Concomitant baseline use of metoclopramide (HR 1.6) was also associated with higher risk of GISE, with weaker associations for tricyclic antidepressants, GABA analogs, and opioids (HRs 1.1–1.2). Model discrimination was modest (C‐index 0.64 training, 0.63 testing). Among 696 symptomatic patients clinically referred for GES after GLP‐1RA initiation, 34.6% ( N = 241) exhibited delayed GE. Constipation was more prevalent in those with delayed GE.
Conclusion
The 5‐year incidence of GISE among patients initiating GLP‐1RA therapy was over 50%. While the ability to predict GISE was modest, female sex, baseline GI symptoms, and concomitant medications were associated with an increased risk. Among the small, symptom‐selected subgroup referred for testing, only a third had delayed GE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Mayo Clinic Platform, Mayo Clinic Rochester, Rochester, Minnesota, USA.
ORCID-Profile: Julio Zuniga Cisneros, Saam Dilmaghani, Ryan J Lennon, Gianrico Farrugia, Michael Camilleri, Madhusudan Grover
Zitieren
APA
Cisneros, J. Z., Lupianez-Merly, C., Dilmaghani, S., Lennon, R. J., Then, S., Fiero, P., Blundo, R., Farrugia, G., Camilleri, M., & Grover, M. (2026). Gastrointestinal Symptom Events and Motility Alterations Associated With GLP ‐1 Receptor Agonists. Neurogastroenterology & Motility, 38(10). https://doi.org/10.1111/nmo.70458
Vancouver
Cisneros JZ, Lupianez-Merly C, Dilmaghani S, Lennon RJ, Then S, Fiero P, et al. Gastrointestinal Symptom Events and Motility Alterations Associated With GLP ‐1 Receptor Agonists. Neurogastroenterology & Motility. 2026;38(10). doi:10.1111/nmo.70458
BibTeX
@article{Cisneros2026,
author = {Cisneros, Julio Zuniga and Lupianez-Merly, Camille and Dilmaghani, Saam and Lennon, Ryan J and Then, Sara and Fiero, Phil and Blundo, Rob and Farrugia, Gianrico and Camilleri, Michael and Grover, Madhusudan},
title = {Gastrointestinal Symptom Events and Motility Alterations Associated With GLP ‐1 Receptor Agonists},
journal = {Neurogastroenterology & Motility},
year = {2026},
volume = {38},
number = {10},
doi = {10.1111/nmo.70458}
}
EUVIMED